RESEARCH 研究の報告

2023.3.31

A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034).

著者 Sakairi Y, Yoshino I, Iwata T, Yoshida S, Kuwano K, Azuma A, Sakai S, Kobayashi K.

J Thorac Dis. 2023 Mar 31;15(3):1486-1493. doi: 10.21037/jtd-22-535. Epub 2023 Mar 6.

PMID: 37065585; PMCID: PMC10089862.

2023.3.2

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.

著者 Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K.

Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2.

PMID: 36966696.

2023.2.1

A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).

著者 Miyanaga A, Asahina H, Watanabe S, Shukuya T, Tsubata Y, Hosomi Y, Sugawara S, Maemondo M, Okano T, Morita S, Matsuyama K, Kobayashi K, Seike M.

Clin Lung Cancer. 2023 Jun;24(4):371-375. doi: 10.1016/j.cllc.2023.01.008. Epub 2023 Feb 1.

PMID: 36849264.

2023.1.31

Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry.

著者 Okuda R, Ogura T, Hisata S, Baba T, Kondoh Y, Suda T, Johkoh T, Iwasawa T, Tomioka H, Bando M, Azuma A, Inoue Y, Arai T, Nakamura Y, Miyamoto A, Miyazaki Y, Chiba H, Ishii H, Hamada N, Terasaki Y, Kuwahira I, Sato S, Kato S, Suzuki T, Sakamoto S, Nishioka Y, Hattori N, Hashimoto N, Morita S, Ichihara N, Miyata H, Hagiwara K, Nukiwa T, Kobayashi K.

Respir Investig. 2023 Jan;61(1):95-102. doi: 10.1016/j.resinv.2022.08.009. Epub 2022 Nov 15.

PMID: 36580379.

2023.1.28

Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.

著者 Tsubata Y, Kawakado K, Hamai K, Furuya N, Yokoyama T, Saito R, Nakamura A, Masuda T, Hamaguchi M, Kuyama S, Honda R, Senoo T, Nakanishi M, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T.

Int J Clin Oncol. 2023 Jan;28(1):69-78. doi: 10.1007/s10147-022-02257-y. Epub 2022 Nov 10.

PMID: 36357710; PMCID: PMC9823025.